| Document |
Document Title |
|
WO/2012/011106 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/098436 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-diene-11-aryl derivatives of formula (I) having an antagonist effect on progesterone, and to a method for the production thereof, to the use thereof for treating and/or...
|
|
WO/2011/098437 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and...
|
|
WO/2011/089541 |
The present invention concerns a method for intracellular delivery of isolated naked nucleic acids into isolated biological tissue or organ, said method comprising at least the steps of: a/ contacting said tissue or organ with an efficie...
|
|
WO/2011/059969 |
Described herein, in certain embodiments, are steroidal derivatives, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor ...
|
|
WO/2011/043913 |
The instant invention provides for novel cationic lipids with short lipid chains that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilit...
|
|
WO/2011/029639 |
The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
|
|
WO/2011/029639 |
The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
|
|
WO/2011/009529 |
The invention relates to a 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11methylene
oxyalkylene aryl derivative of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereo...
|
|
WO/2010/136940 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/126953 |
New chemical entities which comprise corticosteroids and phosphorylated β- agonists for use in therapy and compositions comprising and processes for preparing the same are provided.
|
|
WO/2010/123545 |
Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:
|
|
WO/2010/123545 |
Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:
|
|
WO/2010/118699 |
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.
|
|
WO/2010/118025 |
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
|
|
WO/2010/102673 |
The present invention relates to new cardiotonic Steroid Compounds of Formula (I) or (II) wherein X1, X2, X3, L, R1, R2, R3, R4, and R5 have the same meaning as that defined in the Claims. The invention also relates to the use of said Co...
|
|
WO/2010/091306 |
Prodrugs of C-17-heterocyclic- steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androge...
|
|
WO/2010/091303 |
Steroidal C-17 nitrogen-containing heterocycles of Formula I:,wherein: the ABCD ring structure is the nucleus of a steroid, or an analog thereof,; X is a group capable of coordinating a heme group of CYP 17, and Y is an hydroxyl function...
|
|
WO/2010/060215 |
Novel chemical agents of Formula I are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are dis...
|
|
WO/2010/062562 |
The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.
|
|
WO/2010/012904 |
The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives, and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular as neuroprotective, cardioprote...
|
|
WO/2010/012904 |
The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives, and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular as neuroprotective, cardioprote...
|
|
WO/2010/000070 |
The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous...
|
|
WO/2009/135449 |
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...
|
|
WO/2009/132020 |
This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each ...
|
|
WO/2009/120565 |
Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of...
|
|
WO/2009/120565 |
Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of...
|
|
WO/2009/117120 |
The present invention provides a purification method for air sensitive steroids, by reacting an amino acid or an analogue thereof with the 21-aldehyde oxidation product of such air sensitive steroids to form an adduct that is separated f...
|
|
WO/2009/085879 |
|
|
WO/2009/085880 |
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the gener...
|
|
WO/2009/085880 |
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the gener...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/085880 |
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the gener...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/054531 |
Disclosed is a liquid crystal aligning agent containing a radiation-sensitive polyorganosiloxane which is obtained by reacting a compound represented by the formula (1) below with a polyorganosiloxane having an epoxy group. (In the formu...
|
|
WO/2009/047006 |
An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mix...
|
|
WO/2009/047101 |
New aminooxime derivatives at position 3 of 2-and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as he...
|
|
WO/2009/016648 |
A novel regioselective process for preparing (2ß, 3a, 5a, 16ß, 17ß)-17 acetoxy-3- hydroxy-2- (4-morpholinyl)- 16- (1-pyrrolidinyl) androstane, a known intermediate in the preparation of skeletal muscle relaxant rocuronium bromide in h...
|
|
WO/2009/016648 |
A novel regioselective process for preparing (2ß, 3a, 5a, 16ß, 17ß)-17 acetoxy-3- hydroxy-2- (4-morpholinyl)- 16- (1-pyrrolidinyl) androstane, a known intermediate in the preparation of skeletal muscle relaxant rocuronium bromide in h...
|
|
WO/2008/155141 |
A facultative cationic sterol derivate, said sterol derivate has a pka value of between 3.5 and 8 and the general formula Cation-Spacer 2-Y-Spacer 1-X-Sterol wherein X and Y are linking groups and wherein at least on of X and Y is -NH(C=...
|
|
WO/2008/155141 |
A facultative cationic sterol derivate, said sterol derivate has a pka value of between 3.5 and 8 and the general formula Cation-Spacer 2-Y-Spacer 1-X-Sterol wherein X and Y are linking groups and wherein at least on of X and Y is -NH(C=...
|
|
WO/2008/124922 |
Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, a...
|
|
WO/2008/109033 |
Described herein are steroid derivatives of fullerene moieties, for example fullerene derivatives in which cholesterol, or a cholesterol moiety, is attached via ester, amide, or ether bonds to one of a variety of "linkers," e.g., chemica...
|
|
WO/2008/093086 |
The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
|
|
WO/2008/065100 |
This invention relates to novel substituted estratrien derivatives of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder requiring the inhibition of a 17β...
|
|
WO/2008/034796 |
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease ...
|
|
WO/2008/034796 |
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease ...
|
|
WO/2007/140380 |
In various aspects, the present teachings provide labeling reagents and sets of labeling reagents containing one or more heavy atom isotopes for the relative quantitation, absolute quantitation, or both, of hydroxylated compounds includi...
|
